Statement: The the secondary trial intervention is applied to the palms and soles twice daily, the primary trial participants are not administered any medication topically.
Primary_evidence: INTERVENTION 1:    Lapatinib Plus Paclitaxel   Participants received lapatinib 1500 mg orally OD with paclitaxel, administered as a 1-hour IV infusion at a dose of 80 mg/m^2 on Days 1, 8, and 15 (±2 days) of a 28-day treatment cycle for at least 6 months. Participants were treated until disease progression, unacceptable toxicity, or consent withdrawal.
Secondary_evidence: INTERVENTION 1:    Urea/Lactic Acid Cream   Patients receive topical urea/lactic acid-based cream applied to palms and soles twice daily. INTERVENTION 2:    Placebo Cream   Patients receive placebo cream applied to palms and soles twice daily.